DualityBio Signs Global ADC Partnership with Genentech (Roche) with $45M Upfront Payment
Nashnova编辑部
DotBio signed a global ADC collaboration with Roche's Genentech, collecting US$45 million upfront with potential milestones exceeding US$1 billion — the first time its proprietary DUPAC platform has secured a multinational pharma's global license, validating the platform's technology externally.
What exactly did the two sides sign?
DotBio (09606) and Genentech, a member of the Roche Group, signed a collaboration and license agreement on August 27, 2026.
The deal is built on DotBio's DUPAC platform — a technology that designs novel "warheads" for ADCs (antibody-drug conjugates, medicines that attach a chemo warhead to an antibody so the drug kills only cancer cells).
This means → DUPAC has landed its first global license from a major multinational pharma, effectively a vote of confidence backed by real dollars.
How is the money split and who does what?
DotBio receives US$45 million upfront, plus potential development, regulatory, and commercial milestones totaling over US$1 billion.
Once approved products reach market, DotBio will also earn tiered royalties on annual net sales.
Division of labor: DotBio leads drug discovery and early-stage global clinical development; Genentech gets a worldwide exclusive license and takes over further development and commercialization after Phase 1a completion.
In plain terms = DotBio does the early R&D to prove the drug works; Roche takes the baton for large-scale trials and global sales — each side earns on its own stretch.
Why was the DUPAC platform picked?
DUPAC is one of DotBio's four ADC platforms, purpose-built to overcome tumor resistance to existing ADC warheads.
In plain terms = some tumors no longer respond to the mainstream chemo payloads used in today's ADCs. DUPAC's novel warheads — DUP5, DUP9, DUP10 — use different killing mechanisms, specifically targeting tumors that have stopped responding to older drugs.
Preclinical data have been presented at AACR 2025 and AACR 2026, showing activity in tumor models insensitive to topoisomerase-inhibitor payloads — a common ADC warhead class — with good tolerability in non-human primates.
What should investors watch next?
Whether milestone payments materialize hinges on the collaboration projects completing Phase 1a and successfully transferring to Genentech for later-stage development.
This means → the US$45 million upfront is already banked, but the bulk — over US$1 billion — depends on clinical data. This is a "collect the deposit now, prove efficacy later" deal.
This reflects a broader shift in the ADC race: competition is moving from "who has a platform" to "whose warhead can beat resistance." DotBio has won an entry ticket, not the final prize.
市场有风险，内容仅供研究参考，不构成投资建议。